Andrea M Kellerman Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 Dennis Dr, Special Services -- Claim Care, Bismarck, MO 63624 Phone: 573-734-6111 Fax: 573-734-2957 |
Kelley B Gray Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Bismarck R-v School District, 101 Dennis Dr, Bismarck, MO 63624 Phone: 573-734-6111 Fax: 573-734-2957 |
Mrs. Victoria Nicole Eftink, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 165 Campus Dr, Bismarck, MO 63624 Phone: 573-734-6111 |
News Archive
When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.
Dyadic International, Inc., a leading-edge biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the quarter ended March 31, 2010.
Bose Corporation has introduced DuraPulse™, a new instrument for accelerated durability testing of heart valve replacement devices. Featuring proprietary Bose® controls and linear motor technology, the DuraPulse system enables research and development engineers to run tests at frequencies higher than ever before - exceeding 30 Hz without the loss of waveform fidelity. And with Bose PeakIQ™ control technology, the DuraPulse system also prevents high-pressure spikes during valve closing.
Mississippi state Insurance Commissioner Mike Chaney said Wednesday that the volume of changes under the federally mandated health care reform are 'mind boggling' and partly come from 'pure socialist communist ideas.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that its Board of Directors has authorized the purchase of up to $25 million of its common stock through the end of 2012.
› Verified 5 days ago